about
Radiotherapy for advanced-stage aggressive non-Hodgkin lymphomaBendamustine for patients with indolent B cell lymphoid malignancies including chronic lymphocytic leukaemiaAnthracycline-containing regimens for treatment of follicular lymphoma in adultsComparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphomaAnthracyclines-containing regimens for treatment of follicular lymphoma in adultsFluid and diuretic therapy for preventing cisplatin-induced nephrotoxicityBendamustine for patients with B cell lymphoid malignanciesRole of rituximab for first-line or relapsed aggressive B-cell lymphomaChemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphomaRituximab as maintenance therapy for patients with follicular lymphomaFluid and diuretic therapy for preventing cisplatin-induced nephrotoxicityInhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemiaGuidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelinesPhase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkersThe evolving role of response-adapted PET imaging in Hodgkin lymphomaPET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular LymphomasEmerging treatments in Castleman disease - a critical appraisal of siltuximabSystematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapyNext-generation prognostic assessment for diffuse large B-cell lymphomaHelicobacter pylori infection in gastric mucosa-associated lymphoid tissue lymphomaThe role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage diseaseThe use of FDG-PET in diffuse large B cell lymphoma (DLBCL): predicting outcome following first line therapyManagement of mantle cell lymphoma in the elderly patientWhole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studiesBiomarker validation: common data analysis concernsPrognostic value of interim and end-of-treatment FDG-PET in follicular lymphoma: a systematic reviewGuidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.Correlation of pretreatment 18F-FDG uptake with clinicopathological factors and prognosis in patients with newly diagnosed diffuse large B-cell lymphoma.Advances in the treatment of relapsed or refractory Hodgkin's lymphomaReview of siltuximab in the treatment of multicentric Castleman's diseaseThe Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in The New Drugs EraAssessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working PartyOutcomes of both abbreviated hyper-CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10-year single-centre experience with literature reviewApproach to therapy of diffuse large B-cell lymphoma in the elderly: the International Society of Geriatric Oncology (SIOG) expert position commentaryMature B cell neoplasms: retrospective analysis of 93 cases diagnosed between 2011 and 2014 in a University Hospital in southern BrazilGuidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapyStereotyped patterns of B-cell receptor in splenic marginal zone lymphomaTargeting BTK with ibrutinib in relapsed chronic lymphocytic leukemiaB-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
P2860
Q24187708-3B5612B6-C9A2-43A3-94B8-450BD8BBE998Q24200280-50759CFC-02FD-4AA4-96C6-1149657798CCQ24201306-496B861D-6780-4CA2-98EC-2C837129CC62Q24234975-B420D07F-1A6F-4D02-844C-6FF988374831Q24236087-4EC556E5-7945-4477-93CA-F6FD686528B8Q24236119-CB3932D2-DCD9-4EA1-819E-FF6299E5C1CFQ24236426-6FCEAD01-9BA3-40F3-9BAD-D9876C7D50C2Q24236580-3C00C265-EF2B-450A-A38F-9B85D3C805EDQ24236589-E912F6B6-C7F3-4DC8-AD90-477760565F70Q24241273-39E9D517-EF09-4101-AEE9-305F958C2842Q24242032-AD6A341B-4748-4B34-9D32-33333200765AQ24599100-8A7DBD55-294E-42EC-B3E2-2D18972525E6Q24616084-7625EEB0-F40D-4026-8DA8-2EB91AD4AF81Q24646379-9D20E31F-1A7E-4A83-A4DB-69548B8517E9Q26750993-34AD1B1A-2BFC-4721-994D-37F5942770F2Q26752284-E6605552-1A34-48F6-8C3F-B22947B3940FQ26766554-793E0D1C-7218-4B66-9591-F125F771171EQ26781731-23660075-E076-4CE4-B5F6-119443868F4CQ26796428-95B6D7C0-79FC-40FE-9E65-49D122064554Q26851987-A2BA814D-3795-4640-9AF5-DA9B5FDCDBABQ26858893-CABFB764-2997-4389-AB26-1CF491C730A3Q26863624-C8132E4A-3580-4764-B284-426376A567C0Q26999395-96ECE6CE-94FA-492C-8000-42B4C1214272Q27009307-6A1DEB96-5BC8-4B23-A3E5-A70EDDF98F53Q27024057-E0442E97-662B-4226-AC7E-8D2E357A61B2Q27027445-97758CD4-F99A-4B6E-97C1-5462F7E8207CQ27027579-28F024F5-447B-4C4B-AC3E-144103E021DAQ27314782-C08A901D-B6E1-44CD-BD87-8962F634B8E7Q27314809-87651E2A-0652-40A8-B501-07EDA274E375Q27694504-89CB344B-7304-48F4-BA82-A16A7002882BQ28067246-9664A37B-0991-4784-B062-B1560EC22707Q28072397-C4121F17-C984-4FCF-B82B-5C016E1EC2FEQ28073223-94F7DB22-C2CA-49B6-BC01-3E60966E4320Q28087748-A698BCC2-060A-4052-A34A-24EF02F31201Q28088365-4D60A8B2-028C-4512-A28E-784FA518C20FQ28395001-EEB0FBFE-249C-4089-8C81-F6D9C41E5E2AQ28731819-A49A304F-2EE6-4730-A1E0-73BA223CCCE8Q29048186-E700A32B-550F-42A6-8AAE-BABA5E8011A1Q29620690-84024F8F-2A0F-40CD-9799-39EF28347915Q29620717-8BE34D6D-962B-4112-9BFC-DDD8B11D1CDD
P2860
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Revised response criteria for malignant lymphoma.
@en
Revised response criteria for malignant lymphoma.
@nl
type
label
Revised response criteria for malignant lymphoma.
@en
Revised response criteria for malignant lymphoma.
@nl
prefLabel
Revised response criteria for malignant lymphoma.
@en
Revised response criteria for malignant lymphoma.
@nl
P2093
P50
P356
P1476
Revised response criteria for malignant lymphoma.
@en
P2093
Anton Hagenbeek
Beate Pfistner
Bertrand Coiffier
Bruce D Cheson
Emanuele Zucca
International Harmonization Project on Lymphoma
Kensei Tobinai
Malik E Juweid
Martin Dreyling
Massimo Federico
P304
P356
10.1200/JCO.2006.09.2403
P407
P577
2007-01-22T00:00:00Z